FDA Approved: LEUKERAN — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

FDA supplemental application for Leukeran (chlorambucil) submitted by Waylis Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Leukeran (chlorambucil)

Snippet

SUPPL AP for LEUKERAN (CHLORAMBUCIL)